Pfizer, Inc. (PFE) Covered Calls

Pfizer, Inc. covered calls Pfizer Inc. is a leading global biopharmaceutical company dedicated to discovering, developing, and manufacturing innovative medicines and vaccines. With a massive portfolio spanning oncology, immunology, cardiology, and infectious diseases, the company leverages cutting-edge science and its world-class manufacturing scale to address some of the world’s most critical health challenges and drive the next generation of life-changing breakthroughs.

You can sell covered calls on Pfizer, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for PFE (prices last updated Fri 4:16 PM ET):

Pfizer, Inc. (PFE) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
27.58 +0.11 27.58 27.62 36.8M 16 156
Covered Calls For Pfizer, Inc. (PFE)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 27.5 0.34 27.28 0.8% 36.5%
Mar 20 28 0.64 26.98 2.4% 24.3%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Pfizer Inc. (PFE) is a global powerhouse in the biopharmaceutical industry, currently executing a strategic pivot to move past the pandemic era. Under its "Changing Patients’ Lives" mission, Pfizer is leveraging the massive capital generated from its COVID-19 franchise to aggressively expand its oncology, metabolic, and specialty care portfolios. By integrating high-value acquisitions and advancing a robust late-stage pipeline, the company aims to offset upcoming patent cliffs and establish a new baseline for sustainable, long-term growth.

Core Business and Therapeutic Segments

  1. Oncology: Following the transformative acquisition of Seagen, oncology has become Pfizer’s primary growth engine. The segment focuses on next-generation therapies, including Antibody-Drug Conjugates (ADCs) like Padcev and Adcetris, alongside established blockbusters like Xtandi and Ibrance. In 2026, Pfizer is launching over a dozen pivotal oncology trials to solidify its leadership in breast, genitourinary, and thoracic cancers.
  2. Primary Care: This segment encompasses internal medicine and vaccines. It includes the Prevnar family of pneumococcal vaccines and the blockbuster anticoagulant Eliquis. A major 2026 focus is the "Obesity Strategy," centered on PF-08653944, an ultra-long-acting GLP-1 receptor agonist acquired via Metsera, which recently showed strong Phase 2b weight-loss results.
  3. Specialty Care: Focused on immunology and rare diseases, this segment features the Vyndaqel family for cardiomyopathy and Hympavzi for hemophilia. In early 2026, Pfizer is prioritizing the commercial rollout of on! PLUS and other respiratory syncytial virus (RSV) solutions like Abrysvo to diversify revenue away from legacy products.
  4. COVID-19 Products: While significantly diminished from pandemic peaks, Comirnaty and Paxlovid remain essential components of the infectious disease portfolio. In 2026, the company is managing these products as a predictable, high-margin endemic business.

Competitive Landscape

Pfizer operates in an environment where innovation cycles and patent protection are the primary determinants of success. Its most direct rivals in the global pharmaceutical space include Merck & Co. and Johnson & Johnson. In the high-stakes oncology market, it contends with AstraZeneca and Bristol-Myers Squibb. As it pushes into the lucrative weight-loss (GLP-1) market, it faces entrenched competition from Eli Lilly and Novo Nordisk. Additionally, its vaccine business competes with GSK and Moderna.

Strategic Outlook and Innovation

In 2026, Pfizer is focused on "Execution and De-leveraging." Having spent tens of billions on acquisitions like Seagen and Metsera, the company is now prioritizing cost realignment to protect its industry-leading dividend while funding a record-breaking R&D pipeline. The strategic priority for the year is the start of approximately 20 pivotal Phase 3 trials, including 10 dedicated to its ultra-long-acting obesity assets. The company is also integrating "Agentic AI" across its clinical trial design to accelerate recruitment and reduce time-to-market for new molecular entities. While facing near-term headwinds from loss-of-exclusivity for legacy products, management remains committed to a balanced capital allocation strategy that maintains the current payout while aggressively pursuing "first-in-class" breakthroughs. By 2027, Pfizer aims to have replaced a significant portion of its pandemic-era revenue with a more diversified, high-growth oncology and metabolic portfolio.